A New Hope in Cancer Treatment

In an exciting development for high-grade neuroendocrine cancer patients, a new clinical trial has just opened at the Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine. This innovative study promises to offer fresh hope to those battling this aggressive form of cancer that has seen little advancement in treatment options.

The Challenge of High-Grade Neuroendocrine Cancer

High-grade neuroendocrine cancer is notoriously difficult to treat, with few options beyond traditional chemotherapy. This form of cancer, characterized by its complexity and rarity, often leads to dismal survival rates. Tragically, patients frequently succumb within just one to two years after diagnosis.

Meet Dr. Aman Chauhan: The Visionary Leading the Charge

At the helm of this groundbreaking trial is Dr. Aman Chauhan, a dedicated expert in neuroendocrine tumors. His mission is to provide a new treatment paradigm that utilizes a unique combination of therapies, including cutting-edge immunotherapies and oncolytic viruses that directly target tumors.

Who is at Risk?

Neuroendocrine tumors can emerge from cells throughout the body, affecting multiple systems, particularly the lungs, gastrointestinal tract, and reproductive organs. While mostly diagnosed in individuals over 60, these aggressive tumors can affect anyone, regardless of age.

Stories of Courage